United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
Business Wire•30/09/2026•19:09 ET
1
Key Highlights
- ➤Court finds Liquidia (LQDA) induces infringement of two United Therapeutics (UTHR) patent claims.
- ➤Court rules Liquidia (LQDA) failed to prove the patent claims covering Yutrepia are invalid.
- ➤United Therapeutics (UTHR) may seek FDA withdrawal of Yutrepia’s approval and removal from U.S. market.
- ➤United Therapeutics (UTHR) plans to seek monetary damages, potentially including royalties on past Yutrepia sales.
- ➤Court gives parties one week to submit an agreed final judgment, including any FDA-related order.
Expert Statements
Michael Benkowitz, President and Chief Operating Officer of United Therapeutics
“We are pleased with the Court’s decision, which reinforces our significant research and commitment to bring innovative therapies to the patients we serve. Our immediate priority is ensuring that no patient goes without the therapy they need, and we are ready to support a seamless transition to Tyvaso or Tyvaso DPI should PH-ILD be removed from the Yutrepia label. We look forward to working closely with patients, prescribers, and all other stakeholders throughout this process.”
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Get started
Create a free account to read the full story.